I didn't say you were wrong. I said you were irrelevant. This Company sells gum.
Sure the Company sells a CBD gum which is double lab tested which should help it meet all of the new FDA regs coming down the pikearoo....
But it also has a few investments and those investments could bear tremendous fruits.
While Serendipity is a small investment, I think it can be called one of the most best ice cream launches in history. Besides the 30,000 stores committed to selling the pints, they have now come out with ice cream cakes and single serves as well as additional flavors. In addition, One of the biggest food companies in the world just licensed with the Company to launch 3 drinks which should really get the brand more exposure.
As far as my favorite Bio Tech that TAUG holds, I think they control about a million shares/warrants. While many babble on that the warrants are worthless because they are out of the money (AND THEY WOULD BE WRONG), perhaps the warrants are very very much in the money now. i know our millions of warrants are. It will be interesting to see when the next filing comes out.
A few thought I was nuts when I stated that TAUG's holding in that biotech could be worth 10 mil or more. That projection was based on NAurex deal setting the bar at 2 billion dollars after a phase 2b trial. Now we have more bar setting examples, RLMD from $3.75 to $46 and AXSM from $1.92 to a ridiculous high of $88.00. Then there was SAGE that went from $24 to $175 before losing $5 Billion in valuation a couple weeks ago.
Having 4 potential billion dollar drugs in a very hot space could be very relevent to the Company.
And the gum is in a very exciting and growth space. the quality of the CBD in the future will be quite amazing and controlled. We are invested in one private local facility in RI that hydroponically grows the plants. The facility is so sterile it is almost on par with drug manufaturing labs.
Speaking of the FDA, my friend, one CBD drug is already approved by the FDA. My wife was just an expert speaker at a conference in Philly and met another Company that expects readouts in FDA trials this summer.
This is a penny stock. It has several potential avenues to hit home runs but it is still a penny stock. Had the AV 101 readout met the data point a month ago things would be much different. But with the additional patent going out to 2040 and 3 other blockbuster potentials I like where things sit.
Merry Christmas my friend.
